Skip to NavigationSkip to content

Roche signs deal with Skyhawk over molecules that modulate RNA splicing

Published on 17/07/19 at 10:48am

Roche’s Genentech unit has signed a deal with Massachusetts-based firm Skyhawk Therapeutics to develop and commercialise small molecules that modulate RNA splicing.

The deal will see Skyhawk use its drug discovery platform SkyStar to discover and develop treatments for oncology and neurological disease targets.

Genentech will then have exclusive rights to develop and commercialise potential therapeutics while paying Skyhawk upfront payments and royalties.

“Genentech has long been a leader in advancing drug discovery for oncology and neurodegenerative disorders,” said Bill Haney, co-founder and chief executive officer of Skyhawk.

“We look forward to continuing to demonstrate the utility of SkyStar to discover novel RNA splicing modifiers directed to targets important in the treatment of neurodegenerative diseases and cancer. We share Genentech's passion for transforming patients' lives and look forward to working with the Genentech team to potentially expand the treatment options available to patients.”

Dr James Sabry, global head of Pharma Partnering, Roche, added: “Modulation of RNA splicing represents a novel approach for difficult-to-treat diseases. Skyhawk has developed unique expertise in splicing biology, and we are excited to work with their team to discover potential new medicines for patients with cancer and neurodegenerative diseases.”

Louis Goss

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches